Please use this identifier to cite or link to this item:
http://earchive.tpu.ru/handle/11683/80620
Title: | Перспективы развития фундаментальных наук |
Authors: | Боденко, Виталина Васильевна |
metadata.dc.contributor.advisor: | Белоусов, Михаил Валерьевич |
Keywords: | конференции; лекарственные препараты; молекулы аффибоди; сывороточный альбумин; цитотоксические агенты; соляная кислота; экспрессирующие клетки; SKOV3; BT474 |
Issue Date: | 2023 |
Publisher: | Томский политехнический университет |
Citation: | Перспективы развития фундаментальных наук / . — Томск : Изд-во ТПУ, . |
Abstract: | In this study, we conducted an in vitro study comparing the potential of targeted therapeutic drugs containing a cytotoxic agent mc-DM1. The therapeutic potential of using an HER2-targeting Affibody molecule fused to an albumin-binding domain (ABD) to increase half-life and conjugated to the cytotoxic maytansine derivative, MC-DM1, has previously been confirmed. In this study, we also investigated the potential of a targeted therapeutic conjugate that includes an Affibody molecule targeting HER2 and the cytotoxic agent MC-DM1, and the PAS600 polypeptide was the hallmark of the drug design. PAS polypeptides represent a novel class of biosynthetic polymers comprising repetitive sequences of the small proteinogenic amino acids L-proline, L-alanine and/or L-serine. In this study, PAS600 used to increase the half-life of the drug. We conducted in vitro studies comparing the potential of the new (HE)3-ZHER2-Cys/DM1-PAS600 variant molecule with the previously studied (HE)3-ZHER2-ABD-Cys/DM1 molecule |
URI: | http://earchive.tpu.ru/handle/11683/80620 |
Appears in Collections: | Материалы конференций |
Files in This Item:
File | Size | Format | |
---|---|---|---|
conference_tpu-2023-C21_V4_p21-23.pdf | 545,8 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.